Operating Segments (Tables)

9 Months Ended

12 Months Ended

Sep. 30, 2023

Dec. 31, 2022

Operating Segments

Schedule of operating segments

	Three Months Ended
	September 30,
	2023		2022
Revenues
Specialized BioTherapeutics	$	—	$	—
Public Health Solutions		130,440		166,140
Total	$	130,440	$	166,140
Income (loss) from Operations
Specialized BioTherapeutics	$	(705,753)	$	(1,856,553)
Public Health Solutions		(24,819)		(9,578)
Corporate		(1,048,484)		(1,215,113)
Total	$	(1,779,056)	$	(3,081,244)
Amortization and Depreciation Expense
Specialized BioTherapeutics	$	954	$	2,876
Public Health Solutions		159		479
Corporate		476		1,438
Total	$	1,589	$	4,793
Other (Expense) Income, Net
Specialized BioTherapeutics	$	1,683	$	(12,613)
Corporate		114,671		(215,146)
Total	$	116,354	$	(227,759)
Share-Based Compensation
Specialized BioTherapeutics	$	27,427	$	28,343
Public Health Solutions		994		1,054
Corporate		36,979		41,318
Total	$	65,400	$	70,715

	Nine Months Ended
	September 30,
	2023		2022
Revenues
Specialized BioTherapeutics	$	223,870	$	—
Public Health Solutions		370,677		582,843
Total	$	594,547	$	582,843
Income (loss) from Operations
Specialized BioTherapeutics	$	(2,227,430)	$	(5,396,630)
Public Health Solutions		(26,639)		(131,201)
Corporate		(3,306,000)		(5,141,095)
Total	$	(5,560,069)	$	(10,668,926)
Amortization and Depreciation Expense
Specialized BioTherapeutics	$	2,979	$	8,273
Public Health Solutions		496		1,379
Corporate		1,489		11,886
Total	$	4,964	$	21,538
Other (Expense) Income, Net
Specialized BioTherapeutics	$	17,696	$	110,975
Corporate		60,341		(641,768)
Total	$	78,037	$	(530,793)
Share-Based Compensation
Specialized BioTherapeutics	$	82,281	$	85,190
Public Health Solutions		2,982		3,162
Corporate		143,813		132,304
Total	$	229,076	$	220,656

	As of		As of
	September 30,		December 31,
	2023		2022
Identifiable Assets
Specialized BioTherapeutics	$	58,704	$	103,742
Public Health Solutions		70,557		121,290
Corporate		11,173,568		14,054,685
Total	$	11,302,829	$	14,279,717

	For the Years Ended
	December 31,
	2022		2021
Revenues
Specialized BioTherapeutics	$	31,929	$	—
Public Health Solutions		916,982		824,268
Total	$	948,911	$	824,268
(Loss) Income from Operations
Specialized BioTherapeutics	$	(7,614,988)	$	(7,216,450)
Public Health Solutions		26,612		(542,270)
Corporate		(6,650,528)		(5,340,240)
Total	$	(14,238,904)	$	(13,098,960)
Amortization and Depreciation Expense
Specialized BioTherapeutics	$	10,087	$	7,804
Public Health Solutions		1,681		1,301
Corporate		12,794		25,056
Total	$	24,562	$	34,161
Other (Expense) Income, Net
Specialized BioTherapeutics	$	102,320	$	135,409
Corporate		(816,690)		(452,164)
Total	$	(714,370)	$	(316,755)
Share-Based Compensation
Specialized BioTherapeutics	$	138,075	$	136,594
Public Health Solutions		4,804		21,884
Corporate		190,510		203,081
Total	$	333,389	$	361,559

	As of December 31,
	2022		2021
Identifiable Assets
Specialized BioTherapeutics	$	103,742	$	128,645
Public Health Solutions		121,290		146,296
Corporate		14,054,685		26,594,986
Total	$	14,279,717	$	26,869,927